Patents Represented by Attorney, Agent or Law Firm Bozicevic, Field & Francis LLP
  • Patent number: 8308673
    Abstract: Methods and devices for selectively removing an agent from a physiological site, e.g., a physiological efferent fluid collection site, are provided. Aspects of the invention include fluid removal (e.g., aspiration) devices having a fluid removal element and a flow modulator positioned at a distal end of the fluid removal element. The flow modulator is configured to converge intersecting fluid flow paths into the fluid removal element. Also provided are systems and kits for performing the subject methods. The subject invention finds use in a variety of different applications, including the selective removal of both therapeutic and diagnostic agents from a variety of different physiological sites.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: November 13, 2012
    Assignee: Catharos Medical Systems, Inc.
    Inventors: Ali Hassan, Lester John Lloyd, Michael Orth, Mark Yang, Binh Luong, Brian K. Courtney, Peter J. Fitzgerald
  • Patent number: 8309350
    Abstract: The present invention provides a synthetic regulator of protein function, which regulator is a light-sensitive regulator. The present invention further provides a light-regulated polypeptide that includes a subject synthetic regulator. Also provided are cells and membranes comprising a subject light-regulated polypeptide. The present invention further provides methods of modulating protein function, involving use of light. The present invention further provides methods of identifying agents that modulate protein function.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: November 13, 2012
    Assignee: The Regents of the University of California
    Inventors: Ehud Y. Isacoff, Richard H. Kramer, Dirk Trauner, Matthew R. Banghart, Matthew Volgraf, Pablo Ignacio Gorostiza Langa, Katharine Borges
  • Patent number: 8311889
    Abstract: Disclosed herein are computer-implement systems and methods for identifying and analyzing content (e.g., text, images, videos, etc.) published on digital content platforms (e.g., webpages, mobile applications, etc.). Such analysis is then used to determine whether the published content is appropriate for association with (or “hosting of”) a third-party's content. In one embodiment, for example, the systems and methods presented are particularly useful for determining the appropriateness of an image published on a digital content platform, prior to providing an advertisement proximate the image. As such, merchants can avoid associating their advertised products/services with vulgar, obscene, or otherwise inappropriate images that may have a negative impact on their brand or reputation.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: November 13, 2012
    Assignee: Luminate, Inc.
    Inventors: Kristen Lagle Ruiz, Chris Waterson, James R. Everingham
  • Patent number: 8309316
    Abstract: The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: November 13, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Omar D. Perez, Garry P. Nolan, Jonathan M. Irish
  • Patent number: 8303966
    Abstract: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: November 6, 2012
    Assignee: Yisheng Biopharma (Singapore) Pte. Ltd.
    Inventors: Haixiang Lin, Lie Tao Victor Li
  • Patent number: 8304257
    Abstract: Improved methods for preparing thiolate passivated gold nanoparticles are provided resulting in a narrower size distribution. By alternating oxidation and reduction of the particles, after oxidation, the thiolates may be readily displaced with a different thiol, followed by reduction to prevent further reaction. Proteins can be rigidly bound to the gold nanoparticles by binding an scFv for a target protein to the gold nanoparticles, where the scFv prior or subsequent to binding to the gold nanoparticles may be complexed with the target protein. The protein is rigidly held and its structure readily determined using electron microscopy.
    Type: Grant
    Filed: March 8, 2007
    Date of Patent: November 6, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Christopher J. Ackerson, Pablo Jadzinsky, Roger D. Kornberg
  • Patent number: 8303965
    Abstract: The present invention provides a polynucleotide adjuvant composition and methods of use in eliciting an immune response. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with an antigen (e.g., as in a vaccine). The adjuvant compositions of the invention have particular physical properties (e.g., molecular weight, concentration, and pH) which address the need for a safe adjuvant for eliciting an enhanced immune response. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response to an antigenic compound.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: November 6, 2012
    Assignee: Yisheng Biopharma (Singapore) Pte. Ltd.
    Inventor: Haixiang Lin
  • Patent number: 8304233
    Abstract: The subject invention provides a unidirectional site-specific integration system for integrating a nucleic acid into the genome of a target cell. The provided system includes a site-specific integrating expression cassette (INTEC) vector, consisting of (a) a polynucleotide of interest operably linked to a promoter, (b) a single recombination site, and (c) a hybrid recombination site. In using the subject systems for site-specific integration, the INTEC vector and integrase are introduced into the target cell and the cell is maintained under conditions sufficient to provide for site-specific integration of the nucleic acid into the target cell genome via a recombination event mediated by the site-specific recombinase. Also provided are kits that include the subject systems. The subjects systems, methods and kits find use in a variety of different applications, several representative ones of which are described in detail as well.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: November 6, 2012
    Assignees: Poetic Genetics, LLC, The Board of Trustees of the Leland Stanford Junior University
    Inventor: Michele P. Calos
  • Patent number: 8301395
    Abstract: The present invention includes analyte measurement systems, analyte measurement meters, analyte testing devices, cartridges thereof and integrated circuits for use therewith, and further includes methods related to the use of the integrated circuits and, in certain embodiments, to the counting or tracking of parameters related to the cartridges and analyte test devices.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: October 30, 2012
    Assignee: Abbott Diabetes Care Inc.
    Inventors: William Matievich, Jr., Alexander G. Ghesquiere, Ting Chen
  • Patent number: 8299218
    Abstract: This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: October 30, 2012
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Ali Razai
  • Patent number: 8298521
    Abstract: The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: October 30, 2012
    Assignees: The Regents of the University of California, California Institute of Technology
    Inventors: Daniel M. Schwartz, Scott Fraser, Robert H. Grubbs, Justin P. Gallivan, Changjun Yu
  • Patent number: 8298389
    Abstract: In vitro electrochemical sensor that provide accurate and repeatable analysis of a sample of biological fluid are provided. In some embodiments, the sensors have a measurement zone that has a volume less than the volume of the sample chamber. The measurement zone could have a volume of no more than about 0.2 ?L.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: October 30, 2012
    Assignee: Abbott Diabetes Care Inc.
    Inventors: Ting Chen, Alexander G. Ghesquiere
  • Patent number: 8298222
    Abstract: A method is disclosed for disrupting capillary blood flow and trapping materials such as chemotherapeutic agents in undesirable tissue, including cells of a cancerous or non-cancerous tumor. The method involves the placement of electrodes into or near the vicinity of capillary vessels supplying blood to capillaries in the undesirable tissue, and application of electrical pulses causing capillary blood flow disruption. In some cases, the electric pulses irreversibly permeate the cell membranes, thereby invoking cell death. The irreversibly permeabilized cells are left in situ and are removed by the body's immune system. The process may further comprise monitoring blood flow and/or infusion of a material such as a chemotherapeutic agent or marker into the blood.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: October 30, 2012
    Assignee: The Regents of the University of California
    Inventors: Boris Rubinsky, Jon Edd, Liana Horowitz
  • Patent number: 8298759
    Abstract: Compositions and methods are provided for the in vitro synthesis of biological molecules in reaction mixtures comprising anti-foam agents. The reaction mix comprising antifoam agent may be a scaled up reaction, e.g. in reaction volume greater than at least about 15 ?l. Reactions may be performed in various reactors, as known in the art, which include stirred reactors, bubble-column reactors; and the like.
    Type: Grant
    Filed: March 21, 2005
    Date of Patent: October 30, 2012
    Assignee: The Board of Trustee of the Leland Stanford Junior University
    Inventors: Alexei M. Voloshin, James Robert Swartz
  • Patent number: 8298767
    Abstract: Aspects of the present invention are drawn to processes for moving a region of interest in a polynucleotide from a first position to a second position with regard to a domain within the polynucleotide, also referred to as a “reflex method”. In certain embodiments, the reflex method results in moving a region of interest into functional proximity to specific domain elements present in the polynucleotide (e.g., primer sites and/or MID). Compositions, kits and systems that find use in carrying out the reflex processes described herein are also provided.
    Type: Grant
    Filed: August 13, 2010
    Date of Patent: October 30, 2012
    Assignee: Population Genetics Technologies Ltd
    Inventors: Sydney Brenner, Gi Mikawa, Robert Osborne, Andrew Slatter
  • Patent number: 8298158
    Abstract: The present disclosure provides electrode structures and integrated electrode structures having one or more conductive materials coextruded with one or more dielectric materials. The disclosed electrode structures can be configured for use as analyte sensors. Also provided, are methods of making and using the electrode structures and integrated electrode structures described herein.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: October 30, 2012
    Assignee: Abbott Diabetes Care Inc.
    Inventors: Songbiao Zhang, John C. Mazza
  • Patent number: 8295924
    Abstract: A transdermal system for the delivery of an anesthetic or other active therapeutic agent directly to a selected site of injured skin tissue by iontophoresis is disclosed, which utilizes a transdermal skin-worn patch including a donor electrode chamber containing a donor electrode and an amount of an active agent in a form suitable for transdermal delivery in electrical communication with the donor electrode and a return electrode. The patch also contains a source of electric current connected in a circuit with the donor and return electrode, a current regulating device is optionally provided in the circuit for controlling the electrical output of the patch and at least the donor electrode chamber includes a provision for absorbing a quantity of fluid associated with weepage from adjacent injured skin tissue.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: October 23, 2012
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Carter R. Anderson, Russell L. Morris, Robert Cohen
  • Patent number: 8293501
    Abstract: Methods and compositions for performing low background multiplex nucleic acid amplification reactions are provided. Aspects of the invention include contacting a nucleic acid sample with two or more primer pairs for two or more target nucleic acids under template dependent primer extension reaction conditions, e.g., polymerase chain reaction (PCR) conditions. The resultant amplified composition is then contacted with target nucleic acid circularizing reagents, and product circularized target nucleic acids are then selected, e.g., for further amplification. Also provided are systems and kits that find use in practicing embodiments of the inventions.
    Type: Grant
    Filed: September 11, 2007
    Date of Patent: October 23, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Johan Erik Simon Fredriksson, Carl Oscar Fredrik Dahl
  • Patent number: 8295923
    Abstract: A wearable iontophoresis device for the prolonged delivery of a positively charged pharmaceutical species from a salt formulation is disclosed that includes a readily oxidizable metal-based sacrificial anode in the form of a generally planar layer having a connecting area that has a width that is sufficient to insure complete consumption of the oxidizable metal wherein the anode is configured to have a minimum operating life of at least 6 hours under skin-safe conditions, and a drug delivery gel pad in electrical contact with said anode for accommodating a gel containing a positively charged pharmaceutical species in salt form formulated for transdermal delivery.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: October 23, 2012
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Kathleen A. Eischen, Carter R. Anderson, Russell L. Morris
  • Patent number: D669991
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: October 30, 2012
    Assignee: Abbott Diabetes Care Inc.
    Inventors: Matthew P. Presta, Ronaldo F. Carreon, Williams J. Evans